Insider trading

Period: 120 months Stock: HRTX Share of holding: 50% or more × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

20 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

20 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

20 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

20 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
20 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
20 decisions over 120 months Remove this filter
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

20 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
16 Nov 2023
Collard Craig A Chief Executive Officer
Bought
$137.97K 150,000 at 0.92
411%
First buy on file
16 Nov 2023
Forbes William P EVP, Chief Development Officer
Bought
$47.00K 50,000 at 0.94
×13
First buy on file
21 Jul 2023
Morgan Adam Director · indirect
Bought
$3.41M 2,486,744 at 1.37
55.3%
First buy on file
14 Jan 2021
Szekeres David Leslie EVP, Chief Operating Officer
Sold, plan not stated
$14.96K 827 at 18.09
100%
Sold half or more
8 Jan 2021
Szekeres David Leslie EVP, Chief Operating Officer
Sold, plan not stated
$70.22K 3,571 at 19.66
100%
Sold half or more
22 Dec 2020
MANHARD KIMBERLY EVP, Drug Development
Sold, plan not stated
$200.00K 10,000 at 20.00
100%
Sold half or more
1 May 2020
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$16.18K 1,158 at 13.97
100%
Sold half or more
29 Nov 2019
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$624.00K 24,000 at 26.00
100%
Sold half or more
1 May 2019
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$20.92K 1,109 at 18.86
100%
Sold half or more
2 Nov 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$15.12K 494 at 30.62
100%
Sold half or more
1 Oct 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$192.43K 6,000 at 32.07
100%
Sold half or more
2 Jul 2018
Rosen Robert President
Sold, plan not stated 2×
$3.64M 95,531 at 38.15
97.3%
Sold half or more
2 Jul 2018
Hoffman Robert E. CFO & SVP, Finance
Sold, plan not stated 2×
$1.15M 30,000 at 38.17
95.9%
Sold half or more
2 Jul 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated 2×
$225.18K 6,000 at 37.53
100%
Sold half or more
29 Jun 2018
Rosen Robert President
Sold, plan not stated 3×
$5.13M 129,469 at 39.59
98.0%
Sold half or more
19 Mar 2018
Quart Barry D Chief Executive Officer
Sold, plan not stated
$2.98M 100,000 at 29.75
59.5%
Sold half or more
19 Mar 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$540.00K 18,000 at 30.00
100%
Sold half or more
14 Mar 2018
Quart Barry D Chief Executive Officer
Sold, plan not stated
$2.48M 100,000 at 24.75
59.5%
Sold half or more
10 Jan 2018
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$151.68K 7,584 at 20.00
100%
Sold half or more
24 Apr 2017
MANHARD KIMBERLY Executive VP, Drug Development
Sold, plan not stated
$330.26K 21,542 at 15.33
100%
Sold half or more
Showing 1–20 of 20.